Justine M Kahn1, Qinglin Pei2, Debra L Friedman3, Joel Kaplan4, Frank G Keller5, David Hodgson6, Yue Wu2, Burton E Appel7, Smita Bhatia8, Tara O Henderson9, Cindy L Schwartz10, Kara M Kelly11, Sharon M Castellino5. 1. Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA. Electronic address: jk2034@cumc.columbia.edu. 2. Department of Biostatistics, Children's Oncology Group Statistics & Data Center, Gainesville, FL, USA. 3. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Pediatrics: Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. 4. Levine Children's Cancer & Blood Disorders, Carolinas Medical Center, Charlotte, NC, USA. 5. Department of Pediatrics, Emory University School of Medicine, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. 6. Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. 7. Children's Cancer Institute, Joseph M Sanzari Children's Hospital, Hackensack, NJ, USA. 8. Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, USA. 9. University of Chicago Comer Children's Hospital, Chicago, IL, USA. 10. Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, USA. 11. Department of Pediatric Oncology, Roswell Park Comprehensive Cancer Center, Department of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Abstract
BACKGROUND: Adolescents with Hodgkin lymphoma have worse disease outcomes than children. Whether these differences persist within clinical trials is unknown. We examined survival, by age, in patients receiving response-adapted therapy for Hodgkin lymphoma on Children's Oncology Group (COG) trials. METHODS: Patients (aged 1-21 years) diagnosed with classical Hodgkin lymphoma and enrolled between Sept 23, 2002, and Jan 19, 2012, on one of three phase 3 COG trials in the USA and Canada were eligible for inclusion. The three COG trials were defined by risk group according to Ann Arbor stage, B-symptoms, and bulk (AHOD0431 [low risk; NCT00302003], AHOD0031 [intermediate risk; NCT00025259], or AHOD0831 [high risk; NCT01026220]). The outcomes of this study were event-free survival (death, relapse, or subsequent neoplasm) and overall survival. Cox proportional hazards models estimated survival, adjusting for disease and treatment factors both overall and in patients with mixed cellularity or non-mixed cellularity (nodular sclerosing and not-otherwise-specified) disease. FINDINGS: Of 2155 patients enrolled on the three trials, 1907 (88·4%; 968 [50·8%] male and 939 [49·2%] female; 1227 [64·3%] non-Hispanic White) were included in this analysis. After a median follow-up of 7·4 years (IQR 4·3-10·2), older patients (aged ≥15 years) had worse unadjusted 5-year event-free survival (80% [95% CI 78-83]) than did younger patients (aged <15 years; 86% [83-88]; HR 1·38 [1·11-1·71]; p=0·0038). Older patients also had worse unadjusted 5-year overall survival than did younger patients (96% [95% CI 95-97] vs 99% [98-99]; HR 2·50 [1·41-4·45]; p=0·0012). In patients with non-mixed cellularity histology, older patients had a significantly increased risk of having an event than did younger patients with the same histology (HR 1·32 [1·03-1·68]; p=0·027). Older patients with mixed cellularity had significantly worse 5-year event-free survival than did younger patients in unadjusted (77% [95% CI 65-86] for older patients vs 94% [88-97] for younger patients; HR 2·93 [1·37-6·29]; p=0·0039) and multivariable models (HR 3·72 [1·56-8·91]; p=0·0032). Overall, older patients were more likely to die than younger patients (HR 3·08 [1·49-6·39]; p=0·0025). INTERPRETATION: Adolescents (≥15 years) treated on COG Hodgkin lymphoma trials had worse event-free survival and increased risk of death compared with children (<15 years). Our findings highlight the need for prospective studies to examine tumour and host biology, and to test novel therapies across the age spectrum. FUNDING: National Institutes of Health, St Baldrick's Foundation, and Lymphoma Research Foundation.
BACKGROUND: Adolescents with Hodgkin lymphoma have worse disease outcomes than children. Whether these differences persist within clinical trials is unknown. We examined survival, by age, in patients receiving response-adapted therapy for Hodgkin lymphoma on Children's Oncology Group (COG) trials. METHODS: Patients (aged 1-21 years) diagnosed with classical Hodgkin lymphoma and enrolled between Sept 23, 2002, and Jan 19, 2012, on one of three phase 3 COG trials in the USA and Canada were eligible for inclusion. The three COG trials were defined by risk group according to Ann Arbor stage, B-symptoms, and bulk (AHOD0431 [low risk; NCT00302003], AHOD0031 [intermediate risk; NCT00025259], or AHOD0831 [high risk; NCT01026220]). The outcomes of this study were event-free survival (death, relapse, or subsequent neoplasm) and overall survival. Cox proportional hazards models estimated survival, adjusting for disease and treatment factors both overall and in patients with mixed cellularity or non-mixed cellularity (nodular sclerosing and not-otherwise-specified) disease. FINDINGS: Of 2155 patients enrolled on the three trials, 1907 (88·4%; 968 [50·8%] male and 939 [49·2%] female; 1227 [64·3%] non-Hispanic White) were included in this analysis. After a median follow-up of 7·4 years (IQR 4·3-10·2), older patients (aged ≥15 years) had worse unadjusted 5-year event-free survival (80% [95% CI 78-83]) than did younger patients (aged <15 years; 86% [83-88]; HR 1·38 [1·11-1·71]; p=0·0038). Older patients also had worse unadjusted 5-year overall survival than did younger patients (96% [95% CI 95-97] vs 99% [98-99]; HR 2·50 [1·41-4·45]; p=0·0012). In patients with non-mixed cellularity histology, older patients had a significantly increased risk of having an event than did younger patients with the same histology (HR 1·32 [1·03-1·68]; p=0·027). Older patients with mixed cellularity had significantly worse 5-year event-free survival than did younger patients in unadjusted (77% [95% CI 65-86] for older patients vs 94% [88-97] for younger patients; HR 2·93 [1·37-6·29]; p=0·0039) and multivariable models (HR 3·72 [1·56-8·91]; p=0·0032). Overall, older patients were more likely to die than younger patients (HR 3·08 [1·49-6·39]; p=0·0025). INTERPRETATION: Adolescents (≥15 years) treated on COG Hodgkin lymphoma trials had worse event-free survival and increased risk of death compared with children (<15 years). Our findings highlight the need for prospective studies to examine tumour and host biology, and to test novel therapies across the age spectrum. FUNDING: National Institutes of Health, St Baldrick's Foundation, and Lymphoma Research Foundation.
Authors: Frank G Keller; Sharon M Castellino; Lu Chen; Qinglin Pei; Stephan D Voss; Kathleen M McCarten; Stacy L Senn; Allen B Buxton; Rizvan Bush; Louis S Constine; Cindy L Schwartz Journal: Cancer Date: 2018-05-08 Impact factor: 6.860
Authors: Peter F Coccia; Alberto S Pappo; Lynda Beaupin; Virginia F Borges; Scott C Borinstein; Rashmi Chugh; Shira Dinner; Jeanelle Folbrecht; A Lindsay Frazier; Robert Goldsby; Alexandra Gubin; Robert Hayashi; Mary S Huang; Michael P Link; John A Livingston; Yousif Matloub; Frederick Millard; Kevin C Oeffinger; Diane Puccetti; Damon Reed; Steven Robinson; Abby R Rosenberg; Tara Sanft; Holly L Spraker-Perlman; Margaret von Mehren; Daniel S Wechsler; Kimberly F Whelan; Nicholas Yeager; Lisa A Gurski; Dorothy A Shead Journal: J Natl Compr Canc Netw Date: 2018-01 Impact factor: 11.908
Authors: Tara O Henderson; Susan K Parsons; Kristen E Wroblewski; Lu Chen; Fangxin Hong; Sonali M Smith; Jennifer L McNeer; Ranjana H Advani; Randy D Gascoyne; Louis S Constine; Sandra Horning; Nancy L Bartlett; Bijal Shah; Joseph M Connors; John I Leonard; Brad S Kahl; Kara M Kelly; Cindy L Schwartz; Hongli Li; Jonathan W Friedberg; Debra L Friedman; Leo I Gordon; Andrew M Evens Journal: Cancer Date: 2017-09-13 Impact factor: 6.860
Authors: David W Scott; Fong Chun Chan; Fangxin Hong; Sanja Rogic; King L Tan; Barbara Meissner; Susana Ben-Neriah; Merrill Boyle; Robert Kridel; Adele Telenius; Bruce W Woolcock; Pedro Farinha; Richard I Fisher; Lisa M Rimsza; Nancy L Bartlett; Bruce D Cheson; Lois E Shepherd; Ranjana H Advani; Joseph M Connors; Brad S Kahl; Leo I Gordon; Sandra J Horning; Christian Steidl; Randy D Gascoyne Journal: J Clin Oncol Date: 2012-11-26 Impact factor: 44.544
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: Smita Bhatia; Lindsey Hageman; Yanjun Chen; F Lennie Wong; Elizabeth L McQuaid; Christina Duncan; Leo Mascarenhas; David Freyer; Nkechi Mba; Paula Aristizabal; David Walterhouse; Glen Lew; Pamela Helen-Heilge Kempert; Thomas Bennett Russell; Rene Y McNall-Knapp; Shana Jacobs; Ha Dang; Elizabeth Raetz; Mary V Relling; Wendy Landier Journal: JAMA Netw Open Date: 2020-08-03